Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04423718 · ClinicalTrials.gov registry record · Phase 3
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,011
- Enrollment target
NCT04423718 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,011 participants.
The verdict
NCT04423718, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,011 participants
- Enrollment target
Study Summary
In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD). Neovascular AMD is an eye disease that causes blurred vision or a blind spot due to abnormal blood vessels that leak fluid or blood into the light sensitive lining inside the eye (retina). The fluid buildup causes the central part of the retina (macula) responsible for sharp, straight-ahead vision to swell and thicken (edema), which distorts vision.
Interventions
- DRUG Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
- DRUG Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,011 participants |
| Start Date | 2020-08-11 |
| Est. Completion | 2024-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04423718
The ClinicalTrials.gov registry entry for NCT04423718 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,011 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aflibercept High Dose VEGF Trap-Eye (BAY86-5321) is the first listed.
NCT04423718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04423718 about?
NCT04423718 is a clinical study titled "Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye". In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD). Neovascular AMD is an eye disease that causes blurred vision or a blind ...
What is the current status of trial NCT04423718?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,011 participants. The study started on 2020-08-11. Estimated completion is 2024-08-07.
What interventions are being tested in trial NCT04423718?
The interventions under investigation include: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321) (DRUG), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321) (DRUG).
Who is sponsoring clinical trial NCT04423718?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.